Biogen Tumbles 7% On Surprise Rejection For Alzheimer's Drug
Biogen (BIIB) stock tumbled Friday after European regulators rejected its Eisai (ESAIY)-partnered Alzheimer's treatment, saying the side effects are too potent. ↑ X NOW PLAYING Alzheimer's Treatments: How Biogen, Biotechs Are Working Towards A Cure …